Large gap with delayed quotes
Analysis date: 17.10.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 16.09.2025.
Interest
Strong
Strong
Three stars since 17.10.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 10.10.2025 at a price of 94.71.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 17.10.2025.
4wk Rel Perf
2.21%
2.21%
The four-week dividend-adjusted overperformance versus SP500 is 2.21%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 16.09.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.30%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.58%.
Mkt Cap in $bn
20.19
20.19
With a market capitalization >$8bn, ZIMMER BIOMET is considered a large-cap stock.
G/PE Ratio
0.86
0.86
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
11.02
11.02
The estimated PE is for the year 2027.
LT Growth
8.53%
8.53%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
21
21
Over the last seven weeks, an average of 21 analysts provided earnings per share estimates.
Dividend Yield
0.97%
0.97%
The twelve month estimated dividend yield represents 10.70% of earnings forecasts.
Beta
42
42
For 1% of index variation, the stock varies on average by 0.42%.
Correlation
0.31
0.31
Stock movements are strongly independent of index variations.
Value at Risk
15.27
15.27
The value at risk is estimated at USD 15.27. The risk is therefore 14.98%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
24.07.2002
24.07.2002